These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 34814666)

  • 1. The Effects of Cost Containment and Price Policies on Pharmaceutical Expenditure in South Korea.
    Kim W; Koo H; Lee HJ; Han E
    Int J Health Policy Manag; 2022 Oct; 11(10):2198-2207. PubMed ID: 34814666
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of pharmaceutical cost containment policies on doctors' prescribing behavior: Focus on antibiotics.
    Han E; Chae SM; Kim NS; Park S
    Health Policy; 2015 Sep; 119(9):1245-54. PubMed ID: 26119997
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Do cost containment policies save money and influence physicians' prescribing behavior? Lessons from South Korea's drug policy for diabetes medication.
    Kang SO; Kim SJ; Park S; Jang SI; Park EC
    Int J Qual Health Care; 2019 Mar; 31(2):96-102. PubMed ID: 29788203
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmaceutical policies: effects of reference pricing, other pricing, and purchasing policies.
    Acosta A; Ciapponi A; Aaserud M; Vietto V; Austvoll-Dahlgren A; Kösters JP; Vacca C; Machado M; Diaz Ayala DH; Oxman AD
    Cochrane Database Syst Rev; 2014 Oct; 2014(10):CD005979. PubMed ID: 25318966
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The impact of repeated cost containment policies on pharmaceutical expenditure: experience in Spain.
    Moreno-Torres I; Puig-Junoy J; Raya JM
    Eur J Health Econ; 2011 Dec; 12(6):563-73. PubMed ID: 20809092
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effective policy initiatives to constrain lipid-lowering drug expenditure growth in South Korea.
    Bae G; Park C; Lee H; Han E; Kim DS; Jang S
    BMC Health Serv Res; 2014 Mar; 14():100. PubMed ID: 24589172
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Price cuts and drug spending in South Korea: the case of antihyperlipidemic agents.
    Kwon HY; Hong JM; Godman B; Yang BM
    Health Policy; 2013 Oct; 112(3):217-26. PubMed ID: 24075008
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost containment interventions introduced on the community drugs schemes in Ireland-evaluation of expenditure trends using a national prescription claims database.
    Usher C; Tilson L; Bennett K; Barry M
    Clin Ther; 2012 Mar; 34(3):632-9. PubMed ID: 22381716
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Generic Price Regulation and Drug Expenditures: Evidence From Canada.
    Li Y
    Value Health; 2023 Jun; 26(6):833-840. PubMed ID: 36706953
    [TBL] [Abstract][Full Text] [Related]  

  • 10. European healthcare policies for controlling drug expenditure.
    Ess SM; Schneeweiss S; Szucs TD
    Pharmacoeconomics; 2003; 21(2):89-103. PubMed ID: 12515571
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effects of new pricing and copayment schemes for pharmaceuticals in South Korea.
    Lee IH; Bloor K; Hewitt C; Maynard A
    Health Policy; 2012 Jan; 104(1):40-9. PubMed ID: 22000599
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmaceutical policies: effects of financial incentives for prescribers.
    Rashidian A; Omidvari AH; Vali Y; Sturm H; Oxman AD
    Cochrane Database Syst Rev; 2015 Aug; 2015(8):CD006731. PubMed ID: 26239041
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmaceutical policies: effects of reference pricing, other pricing, and purchasing policies.
    Aaserud M; Dahlgren AT; Kösters JP; Oxman AD; Ramsay C; Sturm H
    Cochrane Database Syst Rev; 2006 Apr; (2):CD005979. PubMed ID: 16625648
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of the zero-mark-up drug policy on drug-related expenditures and use in public hospitals, 2016-2018: an interrupted time series study in Shaanxi.
    Yan K; Yang C; Zhang H; Ye D; Liu S; Chang J; Jiang M; Zhao M; Fang Y
    BMJ Open; 2020 Nov; 10(11):e037034. PubMed ID: 33243788
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of a price cut reform on the cost and utilization of antidiabetic drugs in Korea: a national health insurance database study.
    Suh HS; Kim JA; Lee IH
    BMC Health Serv Res; 2018 Jun; 18(1):429. PubMed ID: 29879966
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of delisting nonprescription combination drugs on health insurance expenditures for pharmaceuticals in Korea.
    Park CM; Lee KS; Han E; Kim DS
    Health Policy; 2016 Jun; 120(6):590-5. PubMed ID: 27241339
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of drug price reduction and prescribing restrictions on expenditures and utilisation of antihypertensive drugs in Korea.
    Yoo KB; Lee SG; Park S; Kim TH; Ahn J; Cho MH; Park EC
    BMJ Open; 2015 Jul; 5(7):e006940. PubMed ID: 26179644
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prediction of Change in Prescription Ingredient Costs and Co-payment Rates under a Reference Pricing System in South Korea.
    Heo JH; Rascati KL; Lee EK
    Value Health Reg Issues; 2017 May; 12():7-19. PubMed ID: 28648319
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Issues in drug pricing, reimbursement, and access in China with references to other Asia-Pacific region.
    Chen Y; Schweitzer SO
    Value Health; 2008 Mar; 11 Suppl 1():S124-9. PubMed ID: 18387056
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of new drug pricing systems and new reimbursement guidelines on pharmaceutical expenditures and prescribing behavior among hypertensive patients in Korea.
    Cho MH; Yoo KB; Lee HY; Lee KS; Kwon JA; Han KT; Kim JH; Park EC
    Health Policy; 2015 May; 119(5):604-11. PubMed ID: 25630635
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.